EYES Second Sight Medical Products Inc

Price (delayed)

$6.5

Market cap

$181.41M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.37

Enterprise value

$157.11M

Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in ...

Highlights
The EPS has soared by 82% year-on-year and by 49% since the previous quarter
Second Sight Medical Products's net income has surged by 73% YoY and by 41% QoQ
The company's revenue has shrunk by 100% YoY
EYES's gross profit is down by 40% YoY

Key stats

What are the main financial stats of EYES
Market
Shares outstanding
27.91M
Market cap
$181.41M
Enterprise value
$157.11M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.19
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$8.84M
EBITDA
-$8.74M
Free cash flow
-$8.95M
Per share
EPS
-$0.37
Free cash flow per share
-$0.38
Book value per share
$0.9
Revenue per share
$0
TBVPS
$1.2
Balance sheet
Total assets
$28.15M
Total liabilities
$7.14M
Debt
$2.57M
Equity
$21.01M
Working capital
$20.68M
Liquidity
Debt to equity
0.12
Current ratio
3.98
Quick ratio
3.87
Net debt/EBITDA
2.78
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-86.4%
Return on equity
-154%
Return on invested capital
N/A
Return on capital employed
-41.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EYES stock price

How has the Second Sight Medical Products stock price performed over time
Intraday
-7.14%
1 week
-2.26%
1 month
27.2%
1 year
513.21%
YTD
247.59%
QTD
-21.21%

Financial performance

How have Second Sight Medical Products's revenue and profit performed over time
Revenue
$0
Gross profit
$500,000
Operating income
-$8.87M
Net income
-$8.84M
Gross margin
N/A
Net margin
N/A
The company's revenue has shrunk by 100% YoY
EYES's operating income has soared by 73% YoY and by 40% QoQ
Second Sight Medical Products's net income has surged by 73% YoY and by 41% QoQ
EYES's gross profit is down by 40% YoY

Growth

What is Second Sight Medical Products's growth rate over time

Valuation

What is Second Sight Medical Products stock price valuation
P/E
N/A
P/B
7.19
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 82% year-on-year and by 49% since the previous quarter
EYES's price to book (P/B) is 44% less than its 5-year quarterly average of 12.9
The company's revenue has shrunk by 100% YoY

Efficiency

How efficient is Second Sight Medical Products business performance
The return on equity has surged by 98% since the previous quarter and by 51% year-on-year
The return on assets has surged by 76% since the previous quarter and by 50% year-on-year

Dividends

What is EYES's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EYES.

Financial health

How did Second Sight Medical Products financials performed over time
The total liabilities has increased by 39% QoQ and by 37% YoY
The debt is 88% lower than the equity
EYES's debt to equity has surged by 104% since the previous quarter
The debt has increased by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.